Topic

Neurology: latest medical news

Multiple sclerosis, Alzheimer's, stroke and neuroscience drug development.

1. Saturday, October 24, 2026

   Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2)

   Source: The Lancet

   In two randomised trials, Novartis's oral BTK inhibitor remibrutinib was superior to teriflunomide in relapsing MS while maintaining a favourable safety profile, per the authors. STAT reports it cut relapse rates by a third versus the standard treatment.

   Why it mattersBTK inhibitors have faced liver-safety scrutiny as a class, so the hepatic safety detail in the full paper matters as much as efficacy for neurologists and drug-safety teams.

2. Saturday, October 24, 2026

   FDA Launches New Program to Advance Neuroscience Medical Product Development

   Source: FDA

   FDA announced the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program it says is aimed at accelerating neuroscience medical product development.

   Why it mattersNeuroscience sponsors should watch for how NAIN changes early engagement with FDA and endpoint discussions; the specifics are in FDA's announcement.